In this study we are testing how two drugs, Thymoglobulin ® and verapamil, work together to treat children and young adults with newly diagnosed type 1 diabetes.
There are two parts to this study. In the first part you or your child will be randomly assigned (like flipping a coin) to receive either the study drug Thymoglobulin or a placebo. Then, in the second part, you or your child will again be randomly assigned (like flipping a coin) to receive either the study drug verapamil or a placebo. A placebo is an inactive substance that looks the same and is given the same way as the study drug. If you or your child joins this study, you will come to 16 study visits over about two years at the Barbara Davis Center on the CU Anschutz campus. At these visits we will ask about you or your child's health and do physical exams. We will also take blood samples from you or your child's arm with a needle. We will have you or your child complete mixed meal tolerance tests to see how much insulin your body is making. We will also do ECGs to see how you or your child's heart is beating. You or your child will be paid for all the study visits that you complete.
You or your child may be able to join this study if you are between 6 and 35 years old. You or your child may also be able to join if you weigh at least 30 kilograms. You or your child may also be able to join if you were diagnosed with type 1 diabetes within 100 days of joining the study. Before joining, a study doctor we will do other tests to make sure you meet all of the requirements and it is safe for you to take part in this study.
Protocol Number: 25-1919
Kimberly Simmons, MD, MPH/MSPH
Principal Investigator